TrialCells2019

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.

Alessandra Mangia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.